Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected PI3K-Altered CRC By Ogkologos - September 30, 2025 275 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALASCCA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... December 10, 2024 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 Women in Science: Celebrating with our Women of Influence initiative March 15, 2023 NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses... March 9, 2021 Load more HOT NEWS Improving research with registered reports Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives FDA Authorizes Blood Test for Assessing Risk of Hereditary Cancers
